Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CYAD-02 |
Synonyms | |
Therapy Description |
CYAD-02 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) encoding the Natural Killer Group 2D (NKG2D) receptor and an shRNA molecule targeting MICA and MICB, which may lead to increased anti-tumor activity (Blood 134 (2019): 3931). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CYAD-02 | CYAD02|CYAD 02 | CYAD-02 are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) encoding the Natural Killer Group 2D (NKG2D) receptor and an shRNA molecule targeting MICA and MICB, which may lead to increased anti-tumor activity (Blood 134 (2019): 3931). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04167696 | Phase I | CYAD-02 Cyclophosphamide + Fludarabine | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Recruiting | USA | BEL | 0 |